Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue ...

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and ...

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board, or DSMB, for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study.

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without question, there ...

Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures ...

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures ...

Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers. This is an ASCO Meeting Abstract from the 2025 ...

Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after ...

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...